Spectrum Pharma (SPPI) – StreetInsider.com Reports
-
Assertio Therapeutics (ASRT) Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals (SPPI)
-
Spectrum Pharmaceuticals (SPPI) PT Raised to $1.14 at B.Riley
-
H.C. Wainwright Downgrades Spectrum Pharmaceuticals (SPPI) to Neutral
-
JMP Securities Downgrades Spectrum Pharmaceuticals (SPPI) to Market Perform
-
Spectrum Pharmaceuticals (SPPI) PT Raised to $1.14 at Cantor Fitzgerald
-
Assertio Therapeutics (ASRT) to Acquire Spectrum Pharmaceuticals (SPPI) in Stock and CVR Deal
-
Spectrum Pharma (SPPI) Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services
-
Spectrum Pharmaceuticals (SPPI) PT Lowered to $0.75 at Cantor Fitzgerald
-
Spectrum Pharma (SPPI) Pharmaceuticals Provides Update on ROLVEDON, Reports Q4
-
Spectrum Pharma (SPPI) CMO to Step Down
-
Spectrum Pharmaceuticals (SPPI) PT Lowered to $4 at H.C. Wainwright
-
Spectrum Pharmaceuticals (SPPI) PT Lowered to $4 at H.C. Wainwright
-
Spectrum (SPPI) de-prioritizes poziotinib after receiving CRL from FDA, shares drop
-
U.S. FDA declines to approve Spectrum's lung cancer drug
-
Spectrum Pharma (SPPI) Receives CRL for Poziotonin; Will Focus on Rolvedon
-
B.Riley Downgrades Spectrum Pharmaceuticals (SPPI) to Neutral
-
Spectrum Pharma (SPPI) Tops Q3 EPS by 3c
-
Spectrum Pharma (SPPI) Announces Commercial Availability of ROLVEDON
-
Implied Volatility Movement
-
Spectrum Pharmaceuticals (SPPI) PT Lowered to $6 at H.C. Wainwright
-
Spectrum Pharmaceuticals (SPPI) PT Lowered to $1.50 at B.Riley
-
Spectrum Pharma (SPPI) Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
-
After-Hours Movers: Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on EPS
-
Spectrum Pharma (SPPI) says FDA committee voted 9-4 that current benefits of poziotinib did not outweigh its risks
-
Spectrum Pharma (SPPI) halted, news pending
-
Spectrum Pharmaceuticals (SPPI) PT Lowered to $9 at H.C. Wainwright
-
Spectrum Pharma (SPPI) on Watch After FDA Posts Briefing Documents
-
Pre-Open Stock Movers: Bristol-Myers Jumps on FDA Approval, Carvana Gains on Upgrade
-
Spectrum Pharma (SPPI) Presents Additional Poziotinib Data
-
Spectrum Pharma (SPPI) Announces FDA Approval of ROLVEDON Injection
-
Spectrum Pharma (SPPI) Halted, News Pending
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Stocks with Implied Volatility Movement
-
Spectrum Pharma (SPPI) Appoints Nora E. Brennan as Chief Financial Officer
-
Spectrum Pharma (SPPI) Appoints Brittany K. Bradrick to its Board
-
Spectrum Pharma (SPPI) Announces FDA Acceptance of BLA Resubmission for Eflapegrastim
-
Spectrum Pharmaceuticals (SPPI) PT Lowered to $4 at B.Riley
-
Spectrum Pharma (SPPI) Misses Q4 EPS by 5c
-
Spectrum Pharma (SPPI) Appoints Juhyun Lim to its Board
-
Spectrum Pharma (SPPI) Reports Positive Data for Poziotinib in First-line NSCLC Patients with HER2 Exon 20 Insertion Mutations
-
Spectrum Pharma (SPPI) Announces CFO Resignation
-
Constellation Energy (CEG) Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
-
Spectrum Pharma (SPPI) Announces Strategic Restructuring
-
Spectrum Pharma (SPPI) Announces New Strategic Investment by Hanmi Pharmaceutical
-
Spectrum Pharma (SPPI) Announces Submission of NDA for Poziotinib
-
Spectrum Pharma (SPPI) Announces Management and Board Changes
-
Spectrum Pharma (SPPI) Tops Q3 EPS by 12c
-
Spectrum Pharma (SPPI) Presents Cohort 4 Data of ZENITH20 Clinical Trial
-
Spectrum Pharmaceuticals (SPPI) PT Lowered to $3 at Cantor Fitzgerald
Back to SPPI Stock Lookup